Suggested remit - To appraise the clinical and cost effectiveness of rituximab within its marketing authorisation for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis.
This appraisal has now been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- STA Standard
- ID number:
- 1320
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 January 2024 | Discontinued. This appraisal has now been discontinued. |
| 20 March 2018 - 19 April 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual